DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 214 filers reported holding DENALI THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $828,377 | -39.6% | 40,154 | -13.6% | 0.05% | -37.8% |
| Q2 2023 | $1,371,477 | +21.9% | 46,475 | -4.8% | 0.07% | +5.7% |
| Q1 2023 | $1,124,974 | +172.1% | 48,827 | +228.4% | 0.07% | +159.3% |
| Q4 2022 | $413,451 | +3.9% | 14,867 | +14.7% | 0.03% | -6.9% |
| Q3 2022 | $398,000 | +5.9% | 12,962 | +1.5% | 0.03% | +20.8% |
| Q2 2022 | $376,000 | -18.1% | 12,776 | -10.4% | 0.02% | +26.3% |
| Q1 2022 | $459,000 | -35.0% | 14,254 | -10.0% | 0.02% | -17.4% |
| Q4 2021 | $706,000 | -20.8% | 15,840 | -10.3% | 0.02% | -23.3% |
| Q3 2021 | $891,000 | +324.3% | 17,653 | +560.9% | 0.03% | +328.6% |
| Q2 2021 | $210,000 | – | 2,671 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $219,569,000 | 28.65% |
| ARCH Venture Management, LLC | 5,168,749 | $152,116,000 | 18.54% |
| Casdin Capital, LLC | 1,500,000 | $44,145,000 | 3.73% |
| Flagship Pioneering Inc. | 2,619,968 | $77,106,000 | 2.90% |
| Yiheng Capital Management, L.P. | 1,014,684 | $29,862,000 | 1.71% |
| SECTORAL ASSET MANAGEMENT INC | 202,100 | $5,948,000 | 1.20% |
| GILDER GAGNON HOWE & CO LLC | 1,956,820 | $57,589,000 | 1.03% |
| Artal Group S.A. | 600,000 | $17,658,000 | 0.94% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $158,024,002 | 0.87% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $283,000 | 0.69% |